Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
HOME > REGULATORY
REGULATORY
- No Major Safety Concerns for Moderna, Pfizer COVID-19 Vaccines: MHLW
August 6, 2021
- Results of Guidelines-Related Studies Can Be Used in Public Knowledge-Based Filings for Fertility Treatments: MHLW
August 6, 2021
- Veklury Distribution via Govt Purchase to Continue for Now: MHLW
August 6, 2021
- Council OKs Public Knowledge-Based Filing for New Indication for Fibrinogen
August 6, 2021
- Industry Sees Overhaul of CEA Scheme “Too Early,” Chuikyo Reps Agree
August 5, 2021
- Chuikyo Calls for Balanced Price-Setting for “Specific-Use” Drugs, Sakigake Products
August 5, 2021
- Ofev Faces 10%-Plus Cut in Quarterly Price Review; Veklury Gets Listing but No Copay for Now
August 5, 2021
- Chuikyo to Compile Proposal on SaMD Reimbursement by Year-End
August 5, 2021
- Up to 580,000 Doses of AstraZeneca’s COVID Vaccine to Be Distributed in Tokyo
August 5, 2021
- August Listing OK’ed for Evrysdi, Veklury, Verquvo, 2 CGRP Migraine Meds and More
August 4, 2021
- Trintellix to Face 4.3% Price Cut under CEA Scheme, No Change for Coralan
August 4, 2021
- Delytact Gets 1.43 Million Yen Price Tag
August 4, 2021
- Temodar Label Revised to Erase Caveat for Combo Cancer Therapy
August 4, 2021
- New Pharma Industry Vision to Push Predictability for Investment Recovery: Draft Outline
August 3, 2021
- MHLW’s COVID-19 Guide Adds Chugai’s Cocktail Therapy
August 3, 2021
- Veklury to Join NHI Price List to Enter Normal Distribution Channel; Peak Sales Put at 18 Billion Yen
August 3, 2021
- Lilly’s Selpercatinib Clears Key Panel, in Line for September Approval
August 2, 2021
- Takeda’s Pevonedistat Set to Be 1st Legally Backed Sakigake Drug
August 2, 2021
- AstraZeneca Vaccine OK’ed for Age 40 and Up under Emergency Program
August 2, 2021
- GMP Inspections to Be Conducted Unannounced as Basic Rule: MHLW
July 30, 2021
ページ
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…